AbbVie Shares Data Supporting Long-Term Efficacy of Atogepant for Preventive Migraine
Details : Qulipta (atogepant) is an orally administered, CGRP receptor antagonist specifically developed for the preventive treatment of chronic and episodic migraine in adults.
Product Name : Qulipta
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 04, 2024
Lead Product(s) : Atogepant
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AQUIPTA (atogepant) is the first and only once-daily oral CGRP receptor antagonist in the European Union approved for the prophylaxis of migraine in adults who have four or more migraine days per month.
Product Name : Qulipta
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 17, 2023
Lead Product(s) : Atogepant
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Atogepant
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Qulipta (atogepant) is a calcitonin gene-related peptide (CGRP) receptor antagonist, it is indicated for the preventive treatment of episodic migraine in adults.
Product Name : Qulipta
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 23, 2023
Lead Product(s) : Atogepant
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Atogepant
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
U.S. FDA Approves QULIPTA® (atogepant) for Adults With Chronic Migraine
Details : Qulipta (atogepant) is a calcitonin gene-related peptide (CGRP) receptor antagonist, it is indicated for the preventive treatment of episodic migraine in adults.
Product Name : Qulipta
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 17, 2023
Lead Product(s) : Atogepant
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Pivotal Phase 3 study evaluating QULIPTA™ (atogepant) in adult patients with chronic migraine meets primary endpoint of statistically significant reduction from baseline in mean monthly migraine days compared to placebo across the 12-week treatment per...
Product Name : Qulipta
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 03, 2022
Lead Product(s) : Atogepant
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In both, Phase 3 PROGRESS and Phase 3 ADVANCE studies, for Qulipta (atogepant), demonstrated all doses were well tolerated, and overall safety profiles were consistent with safety findings observed in previous studies for prophylaxis of episodic migraine...
Product Name : Qulipta
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 18, 2022
Lead Product(s) : Atogepant
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : QULIPTA™ (atogepant), as the first and only oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) specifically developed for the preventive treatment of episodic migraine.
Product Name : Qulipta
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 06, 2022
Details : Atogepant (QULIPTA) would be the first gepant (oral calcitonin gene-related peptide [CGRP] receptor antagonist) approved for the broad indication of the preventive treatment of migraine, including episodic and chronic.
Product Name : Qulipta
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 26, 2022
Lead Product(s) : Atogepant
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : QULIPTA™ (atogepant) is the first and only oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) specifically developed for the preventive treatment of episodic migraine.
Product Name : Qulipta
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 28, 2021
Lead Product(s) : Atogepant
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
AbbVie to Present Data From Its Migraine Portfolio at the 2021 International Headache Congress
Details : Results from an open-label, multicenter extension to the pivotal Phase 3 ADVANCE trial evaluate the safety and tolerability of oral atogepant for the preventive treatment of migraine.
Product Name : Qulipta
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 09, 2021
Reset All
